Julia M Baker1,2, Jacqueline E Tate2, Juan Leon3, Michael J Haber4, Virginia E Pitzer5, Benjamin A Lopman1,2. 1. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. 2. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 3. Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. 4. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. 5. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, Connecticut, USA.
Abstract
BACKGROUND: A correlate of protection for rotavirus gastroenteritis would facilitate rapid assessment of vaccination strategies and the next generation of rotavirus vaccines. We aimed to quantify a threshold of postvaccine serum antirotavirus immunoglobulin A (IgA) as an individual-level immune correlate of protection against rotavirus gastroenteritis. METHODS: Individual-level data on 5074 infants in 9 GlaxoSmithKline Rotarix Phase 2/3 clinical trials from 16 countries were pooled. Cox proportional hazard models were fit to estimate hazard ratios (HRs) describing the relationship between IgA thresholds and occurrence of rotavirus gastroenteritis. RESULTS: Seroconversion (IgA ≥ 20 U/mL) conferred substantial protection against any and severe rotavirus gastroenteritis to age 1 year. In low child mortality settings, seroconversion provided near perfect protection against severe rotavirus gastroenteritis (HR, 0.04; 95% confidence interval [CI], .01-.31). In high child mortality settings, seroconversion dramatically reduced the risk of severe rotavirus gastroenteritis (HR, 0.46; 95% CI, .25-.86). As IgA threshold increased, risk of rotavirus gastroenteritis generally decreased. A given IgA threshold provided better protection in low compared to high child mortality settings. DISCUSSION: Postvaccination antirotavirus IgA is a valuable correlate of protection against rotavirus gastroenteritis to age 1 year. Seroconversion provides an informative threshold for assessing rotavirus vaccine performance. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: A correlate of protection for rotavirus gastroenteritis would facilitate rapid assessment of vaccination strategies and the next generation of rotavirus vaccines. We aimed to quantify a threshold of postvaccine serum antirotavirus immunoglobulin A (IgA) as an individual-level immune correlate of protection against rotavirus gastroenteritis. METHODS: Individual-level data on 5074 infants in 9 GlaxoSmithKline Rotarix Phase 2/3 clinical trials from 16 countries were pooled. Cox proportional hazard models were fit to estimate hazard ratios (HRs) describing the relationship between IgA thresholds and occurrence of rotavirus gastroenteritis. RESULTS: Seroconversion (IgA ≥ 20 U/mL) conferred substantial protection against any and severe rotavirus gastroenteritis to age 1 year. In low child mortality settings, seroconversion provided near perfect protection against severe rotavirus gastroenteritis (HR, 0.04; 95% confidence interval [CI], .01-.31). In high child mortality settings, seroconversion dramatically reduced the risk of severe rotavirus gastroenteritis (HR, 0.46; 95% CI, .25-.86). As IgA threshold increased, risk of rotavirus gastroenteritis generally decreased. A given IgA threshold provided better protection in low compared to high child mortality settings. DISCUSSION: Postvaccination antirotavirus IgA is a valuable correlate of protection against rotavirus gastroenteritis to age 1 year. Seroconversion provides an informative threshold for assessing rotavirus vaccine performance. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Entities:
Keywords:
correlate of protection; gastroenteritis; immunoglobulin A; rotavirus; vaccination
Authors: A D Steele; J Reynders; F Scholtz; P Bos; M C de Beer; J Tumbo; C F Van der Merwe; A Delem; B De Vos Journal: J Infect Dis Date: 2010-09-01 Impact factor: 5.226
Authors: D I Bernstein; V E Smith; J R Sherwood; G M Schiff; D S Sander; D DeFeudis; D R Spriggs; R L Ward Journal: Vaccine Date: 1998-02 Impact factor: 3.641
Authors: D I Bernstein; D A Sack; E Rothstein; K Reisinger; V E Smith; D O'Sullivan; D R Spriggs; R L Ward Journal: Lancet Date: 1999-07-24 Impact factor: 79.321
Authors: T Vesikari; A Karvonen; R Prymula; V Schuster; J C Tejedor; R Cohen; F Meurice; H H Han; S Damaso; A Bouckenooghe Journal: Lancet Date: 2007-11-24 Impact factor: 79.321
Authors: Shabir A Madhi; Nigel A Cunliffe; Duncan Steele; Desirée Witte; Mari Kirsten; Cheryl Louw; Bagrey Ngwira; John C Victor; Paul H Gillard; Brigitte B Cheuvart; Htay H Han; Kathleen M Neuzil Journal: N Engl J Med Date: 2010-01-28 Impact factor: 91.245
Authors: Denise T St Jean; Elizabeth T Rogawski McQuade; Jessie K Edwards; Peyton Thompson; James Thomas; Sylvia Becker-Dreps Journal: Vaccine Date: 2022-03-25 Impact factor: 4.169
Authors: Liliana Sánchez-Tacuba; Ningguo Feng; Nathan J Meade; Kenneth H Mellits; Philippe H Jaïs; Linda L Yasukawa; Theresa K Resch; Baoming Jiang; Susana López; Siyuan Ding; Harry B Greenberg Journal: J Virol Date: 2020-08-31 Impact factor: 5.103
Authors: Mark R Zweigart; Sylvia Becker-Dreps; Filemón Bucardo; Fredman González; Ralph S Baric; Lisa C Lindesmith Journal: Viruses Date: 2021-10-09 Impact factor: 5.048
Authors: Ignacio Salamanca de la Cueva; Barbara Pahud; Li-Min Huang; Michael Leonardi; José Garcia-Sicilia; Javier Céspedes; Arturo Abdelnour; Tsuyoshi Tamura; Haruo Kuroki; Nan-Chang Chiu; Miia Virta; Satu Kokko; Michael Horn; Falko Panzer; Jong-Hyun Kim; Lee Jin; Leentje Moerman; Christophe Debacq; Jose Parra; Ana Ugarte; Dan Bi Journal: J Infect Dis Date: 2020-05-04 Impact factor: 7.759